Literature DB >> 25782766

A case with reversible neurotoxicity after 2 years of dementia secondary to maintenance lithium treatment.

Juan Soriano-Barceló1, María Tajes Alonso, María Begoña Portela Traba, Alberte Araúxo Vilar, David A Kahn.   

Abstract

Chronic neurotoxicity caused by lithium salts can be reversible or irreversible and may appear after years of treatment, even at serum levels considered within the usual therapeutic range. The authors present the case of a patient with bipolar disorder who developed dementia at the age of 54 after being treated with lithium carbonate at therapeutic levels for 4 years. Nevertheless, lithium treatment was continued. At age 56, the patient presented with an acute encephalopathy caused by toxic lithium levels, which resolved only after lithium carbonate was discontinued. Full recovery from the dementia, which had started 2 years earlier, occurred only after cessation of lithium. The authors conclude that when patients treated with lithium develop subacute cognitive impairment, the possibility of lithium toxicity should be considered, even if the serum levels are considered within the therapeutic range. A long duration of neurotoxicity associated with lithium treatment does not necessarily indicate an irreversible prognosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25782766     DOI: 10.1097/01.pra.0000462608.02478.16

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  3 in total

1.  Lithium neurotoxicity presenting as dementia with therapeutic serum lithium levels.

Authors:  Sarita Soni
Journal:  BMJ Case Rep       Date:  2019-01-17

2.  Polypharmacy-induced cognitive dysfunction and discontinuation of psychotropic medication: a neuropsychological case report.

Authors:  Jussi Valtonen; Mira Karrasch
Journal:  Ther Adv Psychopharmacol       Date:  2020-04-28

3.  Lithium as a disease-modifying agent for prion diseases.

Authors:  A Relaño-Ginés; S Lehmann; E Brillaud; M Belondrade; D Casanova; C Hamela; C Vincent; S Poupeau; J Sarniguet; T Alvarez; J D Arnaud; J C Maurel; C Crozet
Journal:  Transl Psychiatry       Date:  2018-08-22       Impact factor: 6.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.